Abstract

The spread of the COVID-19 pandemic posed a serious challenge for scientific and clinical medical institutions in terms of research for new multiple sclerosis (MS) treatments. In this review we discuss the associations between coronavirus infection and MS and provide data on the features of MS pathogenetic therapy during a pandemic. We also analyze the ethical aspects of clinical trials, the problems faced by researchers and patients, especially when using immunosuppressive therapy for MS. We provide examples of violations during research caused by the influence of a pandemic, as well as ways of solving them. Improving ethical standards is an essential component of ensuring the safety of MS and other immune-mediated diseases treatment.

Highlights

  • Распространение пандемии коронавирусной инфекции COVID-19 стало серьезным вызовом для научных и клинических медицинских учреждений при проведении исследований новых методов терапии рассеянного склероза (РС)

  • In this review we discuss the associations between coronavirus infection and multiple sclerosis (MS) and provide data on the features of MS pathogenetic therapy during a pandemic

  • We analyze the ethical aspects of clinical trials, the problems faced by researchers and patients, especially when using immunosuppressive therapy for MS

Read more

Summary

Introduction

Распространение пандемии коронавирусной инфекции COVID-19 стало серьезным вызовом для научных и клинических медицинских учреждений при проведении исследований новых методов терапии рассеянного склероза (РС). Актуальные этические вопросы проведения научных клинических исследований препаратов для патогенетической терапии рассеянного склероза в условиях пандемии COVID-19.

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.